Reg Snafu Drives Boston Scientific CDS Wide
The cost of insuring Boston Scientific Corp. debt against default widened 20 basis points, or nearly 13%, from last night’s close after the medical device maker admitted it had neglected to seek regulatory approval for a change in its manufacturing process.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: